海辰药业股价涨5.07%，中欧基金旗下1只基金位居十大流通股东，持有93.7万股浮盈赚取283.91万元

Group 1 - The core viewpoint of the news is that Haisun Pharmaceutical has seen a significant stock price increase, with a 5.07% rise on October 29, reaching 62.83 CNY per share, and a total market capitalization of 7.54 billion CNY [1] - Haisun Pharmaceutical's stock has increased for three consecutive days, with a cumulative increase of 15.62% during this period [1] - The company, established on January 15, 2003, specializes in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] Group 2 - The main revenue composition of Haisun Pharmaceutical includes 87.12% from cardiovascular drugs, 5.69% from antibiotics, and smaller contributions from other categories such as digestive (1.50%) and antiviral (1.47%) drugs [1] - Among the top ten circulating shareholders, a fund under China Europe Fund, specifically the China Europe Enjoy Life Mixed A (010336), has entered the list, holding 937,000 shares, which is 1.14% of the circulating shares [2] - The fund has achieved a year-to-date return of 12.53% and a one-year return of 9.4%, ranking 5532 out of 8155 and 5727 out of 8031 in its category, respectively [2]